Charbonnieres les bains, France

Lyse Santoro

USPTO Granted Patents = 3 

Average Co-Inventor Count = 5.6

ph-index = 3

Forward Citations = 42(Granted Patents)


Company Filing History:


Years Active: 2003-2009

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Lyse Santoro: Innovator in Neurological and Autoimmune Disease Research

Introduction

Lyse Santoro is a prominent inventor based in Charbonnieres les Bains, France. She has made significant contributions to the field of medical research, particularly in the detection and treatment of degenerative, neurological, and autoimmune diseases. With a total of 3 patents to her name, her work is paving the way for innovative therapeutic solutions.

Latest Patents

One of her latest patents involves the use of a polypeptide for detecting, preventing, or treating pathological conditions associated with degenerative, neurological, or autoimmune diseases. This invention focuses on at least one polypeptide comprising a protein fragment that can be utilized in diagnostic, prognostic, prophylactic, or therapeutic compositions. The proteins selected for this invention include those with peptide sequences corresponding to various SEQ IDs, demonstrating a high degree of identity with these sequences.

Career Highlights

Throughout her career, Lyse has worked with notable companies such as bioMérieux, Inc. and bioMérieux Stelhys. Her experience in these organizations has allowed her to develop her expertise in the medical and biotechnological fields, contributing to her innovative research.

Collaborations

Lyse has collaborated with esteemed colleagues, including Dominique Roecklin and Hanno V Kolbe. These partnerships have further enriched her research and development efforts in the medical domain.

Conclusion

Lyse Santoro's innovative work in the field of medical research highlights her commitment to advancing the understanding and treatment of complex diseases. Her contributions are invaluable to the scientific community and hold promise for future therapeutic advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…